nystatin-a1 and Foot-Diseases

The anti-inflammatory effect of Arnica montana 6cH was evaluated using acute and chronic inflammation models. In the acute, model, carrageenin-induced rat paw oedema, the group treated with Arnica montana 6cH showed 30% inhibition compared to control (P < 0.05). Treatment with Arnica 6cH, 30 min prior to carrageenin, did not produce any inhibition of the inflammatory process. In the chronic model, Nystatin-induced oedema, the group treated 3 days previously with Arnica montana 6cH had reduced inflammation 6 h after the inflammatory agent was applied (P < 0.05). When treatment was given 6 h after Nystatin treatment, there was no significant inhibitory effect. In a model based on histamine-induced increase of vascular permeability, pretreatment with Arnica montana 6cH blocked the action of histamine in increasing vascular permeability.

Topics: Acute Disease; Analysis of Variance; Animals; Anti-Inflammatory Agents; Arnica; Carrageenan; Chronic Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Edema; Foot Diseases; Granulation Tissue; Inflammation; Male; Nystatin; Phytotherapy; Plant Extracts; Random Allocation; Rats; Rats, Wistar; Time Factors

Topics: Amphotericin B; Candidiasis; Diabetes Complications; Diabetic Angiopathies; Foot Diseases; Glucose; Griseofulvin; Humans; Injections, Intramuscular; Nystatin; Pyoderma; Skin Diseases; Skin Manifestations; Skin Ulcer; Tolnaftate; Xanthomatosis